Matthew Hall
Associate Clinical Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (25)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Background Radiation therapy (RT) offers pain relief for patients with symptomatic spine metastases. This study compares pain response and quality of life (QOL) between conventional RT or RT and radiofrequency ablation/percutaneous vertebral augmentation (RFA/PVA). Methods This single-center, prospective, randomized phase 2 trial (NCT04375891) enrolled patients with spine metastasis (T5-L5, with 1-2 index sites amenable to RFA) and a minimum Numeric Pain Rating Scale (NPRS) of 5. After stratifying by tumor type (radioresistant vs. radiosensitive), patients were randomized (1:2) to RT or RT+RFA/PVA. The primary endpoint was 3-month pain response. Secondary endpoints included rapidity and duration of pain response, adverse events, and QOL measures. Results The study terminated after enrolling and randomizing 63 patients (79% of planned accrual; 21 RT alone, 42 RT+RFA/PVA). The median baseline NPRS was 10 (interquartile range [IQR] 8-10) for RT and 9 (7.5-10) for RT+RFA/PVA. The primary endpoint of pain control 3 months after treatment was similar between the RT and RT+RFA/PVA arms (50% vs. 48%, P = .92). Complete pain response rates at 3 months were also similar in the RT and RT+RFA/PVA arms (17% vs. 21%, P = .77). The 3-month median NPRS reduction was −4 (IQR, −6 to −1) in both the RT and the RT+RFA/PVA arms. Secondary efficacy endpoints and toxicity rates were comparable. Overall QOL measures including FACT-G, BPI, and EQ-5D scores were also similar between the two treatment arms. Conclusions The addition of RFA/PVA to conventional RT for patients with symptomatic spine metastases did not improve pain control or QOL measures at 3 months.
Year:
2026
Year:
2025
Background Stereotactic radiosurgery (SRS) for patients with brain metastases (BM) is associated with a risk of distant intracranial failure (DIF). This study evaluates the impact of integrating dedicated 3D fast/turbo spin echo (3D-TSE) sequences to MPRAGE in BM detection and DIF prolongation in a histology-agnostic patient cohort. Methods The study population included adults treated with SRS from February 2019 to January 2024 who underwent MPRAGE alone or dual sequence with the addition of 3D-TSE starting from February 2020. Median times to DIF were estimated using the Kaplan–Meier method. Results The 216 study patients who underwent 332 SRS courses for 1456 BM imaged with MPRAGE and 3D-TSE (primary cohort) were compared to a control cohort (92 patients, 135 SRS courses, 462 BM). In the session-wise analysis, the median time to DIF between the cohorts was significantly prolonged in the primary vs. control cohorts (11.4 vs. 6.8 months, P = .029), more pronounced in the subgroups with 1–4 metastases (14.7 vs. 8.1 months, P = .008) and with solitary BM (36.4 vs. 10.9 months, P = .001). While patients relapsing on immunotherapy or targeted therapy did not significantly benefit from 3D-TSE (7.2 vs. 5.7 months, P = .280), those who relapsed on chemotherapy or who were off systemic therapy (including synchronous metastases) exhibited a trend toward longer time to DIF with 3D-TSE integration (14.7 vs. 7.9 months, P = .057). Conclusions Implementing 3D-TSE sequences into SRS practice increases BM detection across all patients and translates into clinical relevance by prolonging time to DIF, particularly in those with limited intracranial disease and those not receiving central nervous system-active agents.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Collaborators (32)
Chandan Kumar
Associate Research Scientist
University of Michigan
Adam Resnick
Director
University of Pennsylvania
Sebastian Waszak
Tenure Track Assistant Professor
University of California, San Francisco
Mariella Filbin
Dana-Farber Cancer Institute
Arul M Chinnaiyan
University of Michigan
Yoshie Umemura
Barrow Neurological Institute
Muni Rubens
Florida International University Herbert Wertheim College of Medicine
Rajen J. Mody
University of Michigan
Heather McCrea
Assistant Professor
University of Miami
minesh mehta
Chair
Florida International University
Anna Schwendeman
-
Timothy Cloughesy
Director of NeuroOncology Program/Professor
Ronald Reagan UCLA Medical Center
Michelle M Kim
University of Michigan
Sriram Venneti
Professor
University of Michigan
Lili Zhao
Professor
Northwestern University
Charles Burant
University of Michigan
Sabine Mueller
Adjunt Associate Professor
University of California
Nathalie Agar
Principal Investigator
Brigham and Women's Hospital
Nicholas Borja
Assistant Professor of Clinical Genetics
University of Miami Miller School of Medicine
Rajan Jain
Professor
NYU Langone Health
Matthew Dun
Professor Paediatric Heamatology/Oncology Research
Hunter Medical Research Institute
Susanne Schmidt
Group Leader
University of Bonn
Carl Koschmann
University of Michigan Medical School
Andrea T. Franson
-
Javad Nazarian
Lead, DMG Research Center
-
Chan Chung
Principal investigator
Daegu Gyeongbuk Institute of Science and Technology
Benjamin M Ellingson
Professor
University of California, Los Angeles
Mustafa Tekin
University of Miami
Daniel R. Wahl
University of Michigan
Jacques Grill
Head day care
Gustave Roussy
Costas A. Lyssiotis
University of Michigan
Sharon L Gardner
Associate Professor (Clinical) of Pediatrics
NYU School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.